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To determine the extent of clinical actinic damage that 
occurred in association with exposure to oral methoxsa-
len photochemotherapy (PUVA), dermatologists at 16 
university centers assessed the wrinkling, telangi-
ectasia, and altered skin markings on the buttocks and 
the dorsa of the hands among 1380 patients treated with 
PUV A. These changes are similar to those seen in skin 
that is chronically exposed to sunlight. After more than 
5 years of prospective study, patients with psoriasis 
exposed to PUV A showed a significant dose-dependent 
increase in the prevalence of clinical actinic degenera-
tion of the skin of the buttocks (p < .05, F-test). The 
prevalence of moderate or severe change among those 
patients exposed to high doses of PUVA (more than 160 
treatments) was low (11 %). The degree of increased 
clinical actinic degeneration noted on the dorsa of the 
hands was also significantly related to total exposure to 
PUVA (p < .05, F-test). 
Our findings indicate that long-term PUVA exposure 
is associated with an increase in clinical actinic degen-
eration of the skin . However, the magnitude of this 
increase is small and, after more than 5 years, is of 
limited clinical consequence to most patients. 
Long-term exposure to oral methoxsalen photochemotherapy 
(PUV A) for the treatment of psoriasis has been shown to 
increase the risk of squamous cell carcinoma and to induce 
macular hyperpigmented lesions known as PUV A lentigines 
[1,2). Skin tumor development is known to be associated with 
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cumulative actinic exposure independent of exposure to PUV A 
[3]. Chronic exposure to sunlight causes histologic, morpho-
logic, and pathologic changes in the skin which make it appear 
more aged. Although it is not simply an acceleration of chron-
ologie aging, which would normally occur in unexposed skin, 
chronic sun damage has been referred to as premature aging, 
actinic degeneration, solar elastosis, and dermatoheliosis. We 
used the clinical judgement of dermatologists to determine not 
only whether clinically similar changes occur in both sun-
exposed and unexposed skin of patients using PUV A, but also 
whether the frequency ofthese changes is related to cumulative 
exposure to PUVA. Clinically, changes in the skin's appearance 
that are associated with chronic exposure to ultraviolet radia-
tion include fi n e wrinkling, telangiectasia, and changes in skin 
markings. We a lso assessed the relationship of clinical changes 
associated with aging and with actinic damage of the skin, 
which we call actinic degeneration (AD), to individua l patient 
characteristics and other exposures. 
METHODS 
One thousand three hundred and eighty patients with psoriasis who 
began PUVA treatment in 16 university medical centers before October 
1, 1976 were enrolled in the PUV A follow-up study. These patients 
were examined before their firs t treatment and at annual in tervals for 
5 years beginning an average of 2 years after their first t reatment. The 
characteristics of the study population a re summarized in Table I. The 
methods of th is study are detailed elsewhere [4,5]. 
Of the 1380 patients enrolled in the study, 94 had died as of July 
1982. For the surviving patients, the average interval from first treat-
ment to last physical examination was 5.7 years. In addition to their 
examination before starting PUV A treatment, these patients had a 
total of 5511 physical examinations recorded after starting treatment. 
The physical examination performed before starting t reatment in -
cluded a physician's assessment of freckling in areas exposed to sun 
and a qualitative estimate of "solar elastosis" on the face, hands, a rms, 
legs, and trunk. Changes in all areas were graded as none, minimal, 
moderate, or severe. One center in t he Northeast with 187 patients did 
not collect comparable pretreatment data so these patients are excluded 
from analyses based on pretreatment data. Assessments of the extent 
of AD on the dorsa of the hands and on the buttocks included an 
overall impression and separate gradings of fine telangiectasia, fine 
wrinkling, and diffuse hyperkeratosis. Freckling was also assessed as 
part of the annual follow-up examination. The examining dermatologist 
graded each of these changes as none, mild, moderate, or severe. 
To determine which variables were related to cl inical AD indepen-
dent of PUV A t reatment, we related AD noted on physical examination 
before starting treatment with PUV A of one normally exposed area 
(dorsa of hands) and of one area that would receive limited non thera-
peutic exposure to UV radiation (the trunk) to patient attributes and 
exposures. The variables analyzed included age, sex, skin type, eye 
color, sun exposure habits, and pre-PUVA UVB radiation exposures 
for psoriasis treatment. 
To determine the frequency and association of AD to PUV A expo-
sure and to identify risk factors for the development of AD after PUVA 
exposure, we examined the degree of AD on buttocks and hands as 
noted on the final examination. In addition, we compared those patients 
who had an increase in the degree of AD on the hands to those whose 
AD assessment of that site had not increased from pretreatment to 
final examination. To determine whether AD persisted, we examined 
the relation between the extent of AD and two treatment variables: (1) 
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TABLE I. Characteristics of patients enrolled in the PUVA follow-up 
study 
Total enrolled 
Percent male 
Age at enrollment 
Percent psoriasis at entry 
Age at onset of psorias is 
PUV A treament to 1982 
" Mean± SD. 
1380 
65 
44 ± 16" 
34 ± 23" 
25 ± 14" 
133 ± 88" 
TABLE II. Distribution of sun exposure habits reported at entry to 
study 
Mostly indoors 
Half and half 
Mostly outdoors 
Percentage of reporting 
patients 
Weekday 
64 
19 
18 
Weekend 
31 
39 
30 
total number of PUV A treatments; and, (2) in terval from last PUV A 
treatment to final examination . 
Before treatment began, skin type was assessed according to an 
individual's previous response to sunlight [4]. Sun exposure histo ries 
were obtained in interviews administered before beginning PUV A 
therapy. Patients were asked about sun exposure during work a nd 
leisure t ime (mostly indoors, outdoors, or half and halO. The frequency 
of various levels of sun exposure in our population is summarized in 
Table II. 
Most patients were cared for at the same center during the nearly 6 
years of the study. Although t he examining physician for an individual 
patient may have changed over the years, t hese physicians had been 
trained by their predecessors and had shared responsibility with t he 
previous exam iners for care and evaluation of patients at t heir center. 
At the t ime of each year's assessment, examiners were not aware of a 
patient's prior grading. 
Statistical Analysis 
In our initial univaria te analysis we related the frequency of mild, 
moderate , or severe AD in an anatomic a rea to t he patient attributes 
and exposures noted above. For those exposures or attributes that were 
shown in our univariate analyses to be significantly re lated to an 
increase in AD, we performed a multivariate analysis to assess the 
relative contribution of each exposure or attribute to t he degree of, or 
change in, AD. For our regress ion analysis, we converted t he qualitative 
assessment of AD to a numeric score (e.g., 0, 1, 2), wh ich represented 
none, minimal (infrequent) , and moderate to severe (frequent), respec-
tively. 
Differences in proportions were assessed using the chi -square or 
Fisher exact test. Our mu ltivar iate analys is used the method of ]east 
squares to determine the relationships of the degree of AD to patient 
attributes and exposures. The F-test was used to determine statistical 
significance. 
RESULTS 
Pre-PUVA Actinic degeneration 
The results of the univariate analysis are summarized in 
Table III. An examination conducted before beginning PUV A 
treatment showed that one-fifth of patients exhibited AD of 
the hands t hat was graded as moderate or severe, but only 6% 
of this group had changes of this magnitude on their trunk. 
Not surprisingly, AD of both sites increased significantly with 
age (p < .001, chi-square test) (Table III) . AD did not vary 
signi ficantly with sex in either anatomic location (p > .2, chi-
square test). AD of the dorsa of the hands was significantly 
more frequent in skin type 1 and less frequent in skin types 5 
and 6 compared to skin types 2, 3, and 4 (p < .05, chi-square 
test, both comparisons). If patients with gray hair (who are 
older and hence more likely to exhibit AD) are excluded, 
patients with red hair had higher frequencies of AD on both 
areas compared to persons with black or brown hair. Persons 
with blond hair had an intermediate frequency of AD. Outdoor 
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TABLE III. Percentages of patients with specific attributes who had 
moderate or severe actinic degeneration (AD) before first treatment 
with PUVA 
Percent of patients with mod· 
Patient attribute erate or severe AD on: 
Dorsa of hands Trunk 
Sex 
Male 21 7 
Female 17 5 
Age 
<33 3 0 
>33 27 9 
Weekday activity 
Outdoors 24 5 
Half and half 23 8 
Indoors 17 6 
Leisure activities 
Outdoors 24 6 
H alf and half 18 6 
Indoors 17 8 
Skin type 
1 30 12 
2 18 7 
3 19 7 
4 23 10 
5 12 0 
activity during work days and weekends was significantly re-
lated to actinic damage of the dorsa of the hands (p < .05, chi-
square test, both comparisons), but not of the trunk (p > .1, 
chi-square test, both comparisons). 
Although t he frequency of AD on the hands and on the trunk 
was significantly higher among persons Jiving in the middle or 
southern states than those enrolled in northern centers (p < 
.05, chi-square test), some of this effect appears to be attribut-
able to the older age of enrolled patients from southern centers. 
A multiple regression analysis t hat related age and geographic 
residence to AD on t he hands indicates that only 5% of the 
variance explained by these two variables was attributable to 
geographic area (with transformation for t hese analyses: north-
ern states = 0, middle states = 1, southern states = 2). This 
suggests that geographic residence was not an important deter-
minant of the severity of AD. AD of both anatomic sites did 
not vary significantly with pre-PUV A exposure to UVB (p > 
.2, chi-square test, both comparisons). The severity of AD on 
the dorsa of the hands and freckling on sun-exposed areas 
before PUVA treatment were significant ly related (p < .05, 
chi-square test). 
Post-PUVA actinic degeneration 
Buttocks. Because of its low frequency, AD was not assessed 
on the buttocks before PUV A treatment. The frequency and 
severity of AD on the buttocks increased with each PUV A 
follow-up examination. At the first follow-up examination (me-
dian interval of 2 years from first treatment), moderate to 
severe change was noted in only 3% of patients, and mild 
change in 25%. At the final examination (median interval of 6 
years from first PUV A treatment), 7% of patients exhibited 
moderate to severe change and an additional 27% showed mild 
change. 
The frequencies of moderate or severe AD on the buttocks 
for a variety of patient attributes are summarized in Table IV. 
Age at entry to the study was significantly related to the 
prevalence of AD on the buttocks (p < .01, F-test). Sex was 
not significantly related to t he frequency of AD (p > .2, chi-
square test) . None of the patients with skin types 5 or 6 
exhibited moderate or severe AD and only 10% of patients with 
t hese skin types (4 patients) showed mild change. Actinic 
damage on the buttocks was not significantly related to eye or 
hair color (p > .2, chi-square test, both comparisons). 
Lifetime UVB exposure for treatment of psoriasis, as re-
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TABLE IV. Percentages of patients with specific attributes who had 
moderate or severe actinic degeneration (AD) on the buttocks 5. 7 years 
after first treatment w1:th PUVA 
Patient attribute 
Sex 
Male 
Female 
Age 
<30 
30-39 
40- 49 
50-59 
60+ 
Skin type 
1 
2 
3 
4 
5, 6 
Percent of patients with 
moderate or severe AD 
• on buttocks 
8 
6 
4 
6 
7 
8 
12 
6 
8 
7 
7 
0 
TABLE V. Percentages of patients with mild, moderate, or severe 
actinic degeneration. on the buttocks 5. 7 years after first treatment with 
PUVA 
Number of treatments 
with PUVA 
< 100 
100- 159 
> 160 
Degree of actinic degeneration on 
buttocks 
None 
73 
64 
51 
Mild 
22 
27 
38 
Moderate or 
severe 
5 
9 
11 
corded on an interview administered 2 years after starting 
treatment with PUVA, was not significantly related to the 
prevalence of AD on the buttocks (p > .2, chi-square test). 
Patients with moderate or severe AD had a significantly higher 
mean number of PUV A treatments than patients who did not 
exhibit any change (155 vs 124, p < .01, F-test) (Table V). 
A multivariate analysis that related both age at entry and 
the total number of PUV A treatments (logarithmically trans-
formed) to the degree of AD indicates that both variables were 
significant predictors of the frequency and severity of AD (p < 
.05, F-test). In this analysis, the number of PUVA treatments 
was more closely correlated with AD than with patient's age. 
The development of AD of the buttocks in association with 
exposure to PUV A does not appear to be rapidly reversible . For 
example, among patients with more than 100 PUVA treat-
ments, there was no significant relationship of the extent of 
AD on the buttocks to the interval since last treatment (p > 
.2, F-test). 
Dorsa of Hands. AD of the dorsa of the hands on final 
examination shared many of the same associations noted before 
treatment was initiated. The frequency and severity of AD 
increased with age (p < .001, F-test). It was less frequent 
among skin types 5 and 6 (p < .05, chi-square test) compared 
to skin types 1 through 4. Men and women had comparable 
frequencies of AD (p > .2, chi-square test). 
The extent of AD noted upon final examination increased 
with the amount of PUV A dose. One-fourth of patients with 
more than 200 PUV A treatments had moderate or severe 
actinic change in this area compared to only 13% of patients 
who had received fewer than 60 PUV A treatments (p < .001, 
chi-square test). 
Clinically, AD of the hands upon final examination was 
significantly related to PUVA exposure and age (p < .005, F-
test) . In a multivariate analysis, exposure to PUVA and age 
were both significantly and approximately equally associated 
with the frequency and extent of observed changes (p < .05, F-
test). 
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In a separate analysis, we compared the extent of each 
patient's AD on first and last examination. When patients 
whose degree of AD increased were compared to those whose 
degree did not increase, we noted that the chance of worsening 
was significantly associated with the number of PUV A treat-
ments a patient had received (p < .05, F-test). 
Actinic Keratoses. Nearly one-fifth (253/1322) of patients 
developed one or more lesions of the dorsa of the hands which 
a participating investigator diagnosed as actinic keratoses. Pa-
tients who developed actinic keratoses were significantly older 
at entry than patients who did not develop such lesions (53 vs 
41, p < .001, F-test). 
Not surprisingly, actinic keratoses were significantly more 
frequent among patients exhibiting AD in an affected area (p 
< .001, chi-square test, both comparisons). In fact, persons who 
had severe AD of the hands at final follow-up had a more than 
17 times higher risk of having an actinic keratosis than persons 
without AD. 
Actinic keratoses of the buttocks were infrequently noted. 
Altogether, 38 patients (3%) developed such lesions in nearly 6 
years of follow-up. In an analysis restricted to persons less than 
60 years old, total PUV A exposure was significantly related to 
the chance of developing such lesions (p < .05, F-test). The 
severity of AD and the risk of developing actinic keratoses in 
this site were significantly related (p < .001 , chi-square test). 
DISCUSSION 
Structural changes in the skin that occur with aging and sun 
exposure alter the skin's clinical appearance. These changes 
have been referred to by a variety of terms including aging, 
actinic change, solar elastosis, dermatoheliosis, and actinic 
degeneration. In this analysis, we referred to these clinically 
apparent alterations as actinic degeneration. Histologic studies 
demonstrate that aging causes changes in all areas of the skin. 
Clinically and histologically, these changes are greatest in sun-
exposed areas. Histologic elastosis also occurs principally in 
sun-exposed areas [6, 7]. At least three types of clinically evident 
morphologic alterations are frequently prominent in skin ex-
hibiting the changes of aging and actinic damage: (1) replace-
ment of fine skin surface markings by deep irregular wrinkles; 
(2) a surface that appears dry and rough; and (3) an increase 
in apparent telangiectasia. 
Long-wave ultraviolet radiation (UV A) penetrates more 
deeply into the dermis than does UVB. Histologic studies have 
demonstrated a variety of changes in the dermis of PUV A-
treated patients which include alterations in elastic fibers [8, 
9), the formation of colloid-amyloid bodies [10] , basement 
membrane thickening, and the development of eosinophilic 
homogenization in the dermis. Long-term PUV A exposure can 
cause AD [9); however, the extent and frequency of AD asso-
ciated with varying levels of exposure to PUV A has not been 
previously assessed in a large population of patients exposed to 
PUV A for more than 5 years. 
Our data demonstrate that the risk of developing clinical 
changes similar to those seen with AD in both normally sun-
exposed and sun-protected skin increases with exposure to 
PUV A and with increasing age. Even among patients with high 
levels of exposure to PUV A (greater than 160 treatments), the 
frequency of substantial AD of the buttocks is relatively low 
(11 %) and severe change is rare (less than 1 %). The extent of 
these changes may increase with further treatment and the 
possibility exists, especially in younger persons, that an insuf-
ficient interval has elapsed for these changes to have fully 
manifested themselves. However, after nearly 6 years, t he de-
velopment of substantial AD which is apparently due to PUV A 
exposure is a problem that appears limited to relatively few 
patients. 
Patients who developed AD on the buttocks by their first 
follow-up physical examination and who subsequently im-
proved had received 2 or more treatments during a higher 
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fraction of weeks up to the time of this examination and were 
more likely to discontinue PUV A therapy than patients not 
exhibiting these changes. Although these observations support 
the hypothesis that actinic damage associated with PUVA 
exposure is partially reversible, the lack of a significant rela-
tionship between the interval since last PUV A treatment and 
the extent of AD suggests that the rate of resolution of AD is 
slow. 
After age is considered, the frequency of AD did not vary 
substantially between geographic areas. This may reflect dif-
ferences in the populations at risk in each area. For example, 
northern centers had the largest populations of patients with 
skin type 1. Also, physicians at southern centers may have had 
different standards for grading AD. Since most patients re-
turned to the same center for their examinations, the in-center 
differences in AD criteria should not have been a substantial 
confounding factor in our analysis of an increase in AD asso-
ciated with PUV A exposure. However, it is possible that as 
physicians in the study became accustomed to seeing such 
changes, they graded these changes more modestly than when 
they were first noted. 
Our failure to note any significant relationship between UVB 
exposure and actinic damage either of dorsa of hands or of the 
buttocks may reflect the relatively small number of patients in 
our cohort who received high doses of UVB before treatment 
with PUV A as well as the relatively low intensity of UV 
radiation used in such treatments before 1976. The cumulative 
effects of high numbers of erythemogenic exposures to UVB as 
they are currently utilized requires additional study. 
After 6 years, the relationship of AD to PUV A is not frequent 
Vol. 84, No. 2 
nor serious. Only long-term surveillance can assure us that 
these clinically important changes will not occur after a longer 
period of time or from greater exposure to PUV A. 
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